• Outset Medical’s third-quarter 2026 net loss narrowed 18% year over year to $14.69 million.
• Revenue rose 14% year over year to $33.6 million, while operating expenses fell 5% to $25.9 million.
• CEO Leslie Trigg cited expanding Tablo adoption among existing customers and new insourced dialysis partnerships with leading health systems.
• Management reiterated its 2026 revenue guidance of $125 million to $130 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041601PRIMZONEFULLFEED9869798) on November 04, 2026, and is solely responsible for the information contained therein.